A comparative study of the real-world safety and effectiveness of metronomic cyclophosphamide and bevacizumab with or without pembrolizumab for recurrent ovarian cancer. This is an ASCO Meeting ...

Folate receptor α (FOLR1) is highly expressed in the surface of tumoral cells in several cancer types, while it shows limited expression in normal tissues. CSPC Pharmaceutical Group Ltd. has developed ...

Optimizing an NGS low-pass–based method to detect genomic instability as a PARP inhibitor predictive biomarker in high-grade serous ovarian cancer. This is an ASCO Meeting Abstract from the 2025 ASCO ...

LY4170156 is an investigational, next-generation ADC targeting Fra, a cell-surface glycoprotein encoded by the gene FOLR1 that binds to the essential nutrients folic acid and reduced folates ...

Guardant Health, Inc. (NASDAQ:GH) announced adding a full suite of immunohistochemistry to its portfolio of tumor molecular ...

4 FOLR1 IHC testing, which helps identify patients with ovarian, fallopian tube, or primary peritoneal cancer whose tumors are folate receptor alpha-positive and who may be eligible for a targeted ...

Foundation Medicine, Inc., a genomics company committed to transforming cancer care, today announced that it has expanded its immunohistochemistry (IHC) test offerings to include MET IHC testing using ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the addition of a full suite of ...

Discovered and developed by Lilly researchers, Verzenio was first approved in 2017 and is currently authorized for use in more than 90 counties around the world. For full details on indicated uses of ...

Preclinical results with its lead candidate MBK-103, targeting the folate alpha receptor (FOLR1), were reported at the American Association of Cancer Research (AACR) meeting in March. The ...